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Letter to the Editor

Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients
with intermediate cytomegalovirus infection risk
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Letter to the Editor,
Cytomegalovirus (CMV) infection and/or disease are
among the most important infectious complications after
kidney transplantation (KT). According to the recent
guidelines, intravenous ganciclovir or oral valganciclovir
chemoprophylaxis is recommended for KT recipients
in high and intermediate risk groups [1,2]. Preemptive
treatment with monitoring weekly CMV DNA without
prophylaxis is an alternative approach in intermediate risk
groups.
Valacyclovir has also been recommended for prophylaxis
at the dose of 8 g/day for kidney transplant recipients [1,2].
Nevertheless, 3-g/day dose of valacyclovir was used in
3-kidney transplant studies that included high-risk patients
and in all three studies it has been emphasized that a dose of
3 g/day provides sufficient protection for CMV [3–5]. In our
institute, a modified preemptive approach, valacyclovir at
the dose of 2 g/day in combination with CMV monitoring,
has been used in KT recipients with intermediate risk (D+/
R+) and low immunological risk. With this letter, we aimed
to share our experience with a special emphasis on middleterm renal outcome, occurrence of CMV infection and/or
disease and cost.
This was a two center, retrospective, observational
cohort study that enrolled KT recipients from 2011 to
2017. In the study group, KT recipients have received 2-g/
day valacyclovir for CMV prophylaxis with CMV PCR
monitoring every 2 weeks through the first 3 months,
then monthly monitoring after the third month until
the sixth month. Study patients were compared with
the corresponding transplant cohort from Cerrahpaşa
Medical Faculty who received Valganciclovir 900 mg/day
prophylaxis for 3 months during the same period. CMV
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PCR levels were not studied routinely in the control group,
but the patients were followed up regarding CMV-specific
symptoms during their regular visits. In both groups,
immunosuppressive treatment protocols and follow-up
protocols were similar.
A total of 62 KT recipients were included in the study
(F/M: 29/33; mean age 33.4 ± 9.6; range: 18–65 years) and
compared to 40 transplant recipients from Cerrahpaşa
Medical Faculty. The demographic and clinical data
of the study groups are summarized in Table 1. The
patients’ characteristics were similar in both groups. In
valacyclovir group, CMV DNAemia with a median
blood level of 238 (range 141–5033) developed in 14
patients (22%) but CMV disease was not diagnosed in
any of the patients. The median time post-transplant to
develop CMV DNAemia was 51 days (range 11–164). In
the control group, none of the patients were diagnosed
with CMV disease. Late-onset CMV disease was not
reported in any of the study groups. There were no reports
of valacyclovir-related neurotoxicity. The incidence of
leukopenia was higher in valganciclovir (Table 2). When
absolute leukocyte counts at third month were compared,
valganciclovir group had statistically significant lower
leukocyte counts than valacyclovir group (7.1 ± 2.7 vs. 9.5
± 3.9 103/mm3; p = 0.001).
There was no significant difference in terms of the
tacrolimus/cyclosporine use, and mean blood levels
between the patients at 12th month of transplantation.
Acute rejection, post-transplant diabetes mellitus, and
coronary artery disease rates at the last visit were similar
in both groups. There was also no significant difference
with regard to glomerular filtration rate values between
the groups (Table 2). Graft and patient survival rates were
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Table 1. Comparison of demographic and clinical data of study groups.
Valacyclovir group (n = 62)

Valganciclovir group (n = 40)

p

Gender (Female/male)

29/33

14/26

0.227

Age (years)

33.4±9.7

36.6 ±13.5

0.163

Primary kidney disease n (%)
Glomerulonephritis
Diabetic nephropathy
Hypertension
Reflux nephropathy
Polycystic kidney disease
Unknown

20 (30.6%)
7 (11.3%)
3 (4.8%)
4 (6.5%)
4 (6.5%)
24 (38.7%)

8 (20%)
5 (12.5%)
1 (2.5%)
11 (27.5%)
0 (0%)
15 (37.5%)

Hepatitis serology n (%)
Hepatitis B
Hepatitis C

4 (6.5%)
1 (1.6%)

1 (2.5%)
0 (0%)

0.472

Immunosuppressive drugs n (%)
Tacrolimus
Cyclosporine

57 (91.9%)
5 (8.1%)

38 (95%)
2 (5%)

0.390

HLA mismatch number (MM)
0–1 MM (n)
2–4 MM (n)
5–6 MM (n)

15
34
13

7
21
12

Donor sex (F/M)

39/23

29/11

0.391

Donor age (years)

48.5 ± 9.6

45.9 ± 10.4

0.204

compared and there was no significant difference between
the groups (Figures 1 and 2). The total cost of valacyclovir
prophylaxis with CMV DNA PCR test was calculated as
878.52 USD whereas, in the valganciclovir group, the total
drug cost was calculated as 3387.9 USD for 3 months of
prophylaxis.
Although the efficacy of valacyclovir at a low dose
(3 g/day) has been suggested previously, we for the first
time demonstrated that the use of even a lower dose of
valacyclovir (2 g/day) is also effective in KT recipients with
no major adverse events and at a lower economic cost even
with preemptive monitoring in every 2 weeks. Sund et al.
have suggested that valacyclovir use at 3 g/day may be used
for CMV prophylaxis emphasizing the need for further
studies in KT recipients even though in vitro studies have
demonstrated the inefficiency of low dose valacyclovir
against CMV [5]. Low-dose valacyclovir prophylaxis
has also been used in other immunosuppressive patient
groups. An effective prophylaxis at a dose of 2 g/day has
been achieved in a study on bone marrow transplantation
patients [6]. In the observation of Kervan et al. on 68
patients with heart transplantation, sufficient CMV
prophylaxis and a preferable cost effectiveness have been
achieved with 1 g/day dose of valacyclovir [7].

0.063

0.512

In our study, CMV DNAemia frequency in the
group that received low-dose valacyclovir is found to
be 22%, and this rate is comparable with the previous
valganciclovir studies [8,9]. In a study that investigated
the efficacy of 3 g/day valacyclovir prophylaxis in KT
recipients, the authors showed a 25% of CMV infection
rate which was also similar to our results even we
used a lower dose of valacyclovir [5]. In our study we
used a modified preemptive approach, which can be
defined as a combination of the two methods: using
valacyclovir prophylaxis with CMV DNA monitoring.
The major advantage of this combined method is that
CMV monitoring would lead to early detection of
breakthrough viral replication. The results of our study
suggest that a modified preemptive approach may be an
option in this specific group. Also, less frequent blood
drawn may also result in an improvement in quality of
life after transplantation.
A trend towards BK viremia was found in the study
group (8% vs. 0%, p = 0.154). It can be majorly attributed
to the increased rejection rate and its consequence
due to increased immunosuppression in our patients.
Interestingly, Reischig et al. suggested that valganciclovir
prophylaxis, which generates further lymphocyte
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Table 2. Clinical outcomes of study groups.
Valacyclovir group (n = 62)

Valganciclovir group (n = 40)

p

GFR at 1 month

71.4 ± 19.2

75.2 ± 21

0.349

GFR at month 3

69.1 ± 21.5

74.3 ± 16.9

0.195

GFR at month 6

73.8 ± 22.3

71.3 ± 16.2

0.557

GFR at month 12

69.1 ± 22.8

74.6 ± 19

0.202

GFR at last visit

63.9 ± 25.2

71.4 ± 20.4

0.119

Hgb at 3 months

12.9 ± 1.6

12.7 ± 1.3

0.516

Hgb at 6 months

13.5 ± 1.8

13.2 ± 1.5

0.350

Wbc at 3 months

9.5 ± 3.9

7.1 ± 2.7

0.001*

Wbc at 6 months

8.5 ± 3

7.6 ± 2.1

0.095

Leukopenia at 3 months (n, %)

6 (9.7%)

8 (20%)

0.153

Mean tacrolimus levels (µg/L)

8.8 ± 1.1

9.4 ± 1.4

0.095

Mean cyclosporine levels (µg/L)

132.8 ± 17

136 ± 34.3

0.862

Acute rejection**

10 (16.1%)

4 (10%)

0.557

Follow up time (months)

42.7 ± 12.1

43.2 ± 12.1

0.861

Posttransplant DM**

4 (6.4%)

8 (20%)

0.057

BK viremia**

5 (8%)

0 (0%)

0.154

Cardiovascular event**

0 (0%)

3 (7.5%)

0.058

Graft loss**

4 (6.4%)

0 (0%)

0.153

Death**

1 (1.6%)

1 (2.5%)

1

GFR (mL/min/1.73 m )
2

Hgb (g/dL)

Wbc (103/mm3)

*: Statistically significant, p < 0.05; **: At the end of follow-up.
GFR: Glomerular Filtration Rate; Hgb: Hemoglobin; Wbc: White blood cell; DM: Diabetes Mellitus.

Figure 1. Kaplan-Meier curve showing graft survival in patients
received valacyclovir and valganciclovir prophylaxis.

1406

Figure 2. Kaplan-Meier curve showing patient survival in
patients received valacyclovir and valganciclovir prophylaxis.
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depletion, might be associated with an increased risk of
BK viremia and CMV DNAemia did not appear a risk for
BKV [10].
The other important issue is cost effectiveness in
prophylaxis studies. The use of valganciclovir causes
difficulties due to the tight monetary policies of the
insurance companies in developing countries as well as in
Europe and the US. It is indicated that valacyclovir even at
a dose of 8 g/day has 44% lower cost than valganciclovir
in the study carried out by Kacer et al. in 2015 [11]. We
found that 75% lower cost was achieved in the patients
who received a low dose of valacyclovir for 6 months
through CMV DNA monitoring when compared to those
on 3 months of valganciclovir prophylaxis.
In conclusion, our data suggest that low dose
valacyclovir prophylaxis at 2 g/day with at least bi-weekly

CMV monitoring for the prevention of CMV disease may
have a place in patients with living kidney transplantation
with intermediate CMV and low immunological risk
status.
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